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Abstract
The We and others have previously shown that polygenic risk 
score analysis (PRS) has considerable predictive utility for 
identifying those at high risk of developing Alzheimer’s disease 
(AD) with an area under the curve (AUC) of >0.8.  However, by 
far the greatest determinant of this risk is the apolipoprotein E 
locus with the E4 allele alone giving an AUC of ~0.68 and the 
inclusion of the protective E2 allele increasing this to ~0.69 in 
a clinical cohort.  An important question is to determine how 
good PRS is at predicting risk in those who do not carry the 
E4 allele (E3 homozygotes, E3E2 and E2E2) and in those who 
carry neither the E4 or E2 allele (i.e. E3 homozygotes). Previous 
studies have shown that PRS remains a significant predictor of 
AD risk in clinical cohorts after controlling for APOE ε4 carrier 
status.  In this study we assess the accuracy of PRS prediction 
in a cohort of pathologically confirmed AD cases and controls. 
The exclusion of APOE4 carriers has surprisingly little effect 
on the PRS prediction accuracy (AUC ~0.83 [95% CI: 0.80-
0.86]), and the accuracy remained higher than that in clinical 
cohorts with APOE included as a predictor.  From a practical 
perspective this suggests that PRS analysis will have predictive 
utility even in E4 negative individuals and may be useful in 
clinical trial design.
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Introduction
Polygenic risk score (PRS) analysis enhances the predictability of the diagnosis of AD (1).  In a recent analysis, we showed that the area under 
the curve (AUC) in a pathologically confirmed case/
control series was 0.84 (2).  However, by far the largest 
contribution to this risk analysis is the E4 allele (risk) 
and the E2 allele (protective) which gave AUC of 0.68 
(E4 alone) and 0.69 (E4+E2) as compared to the overall 
PRS AUC=0.75 in clinical samples (1).  An important 
practical and theoretical consideration is to understand 
how good PRS is when the risk at the APOE locus is 
removed.  When this was tested in the clinical series 
(1) the AUC was reduced from 0.75 in the whole 
dataset to 0.65 in E3 homozygotes. Assessment of the 
significance of PRS adjusting for APOE4 statistically 
was performed (3) and indicated little change in the 
models’ statistical significance. However for practical 
application, e.g. selecting individuals for clinical trials, 
statistical significance is not an informative measure of 
the algorithm performance. To our knowledge, the PRS 
accuracy in E3 homozygotes has never been directly 
investigated in pathologically confirmed samples. 
Therefore, we tested this in our pathological series by 
removing from the analysis, first all E4 carriers and then, 
all E4 and E2 carriers from both the case and the control 
data sets.              
The sample characteristics of the original dataset used 
in this study were the same as in our previous analysis 
(2). This project was declared IRB exempt (MedstarProject 
#2003-118) under the Code of Federal Regulations, 45 
CFR, 46.  The primary data consisted of 1011 cases and 
583 controls.  We first eliminated all those samples who 
had an E4 allele (leaving 354 cases and 454 controls) and 
then additionally those with an E2 allele (leaving 321 
cases and 365 controls homozygous for the E3 allele). 
From the total 36,481,940 imputed single nucleotide 
polymorphisms (SNPs), we excluded those with an Info 
score below 0.8 and MAF<0.01. This resulted in 7,868,100 
SNPs which were used for the analysis. Genome-wide 
association analysis was performed for each SNP 
using logistic regression analysis as implemented in 
snptest (4) with adjusting for gender and first two 
principal components which were selected after visual 
inspection of each pair of PCs to adjust foe any potential 
stratification in the data
Predictive modelling was performed using a 
polygenic score approach based upon AD associated 
SNPs according to the IGAP study (5). We converted the 
imputed genotypes of our samples into “most probable” 
genotypes with a probability over 90%. The correlated 
SNPs were pruned using parameters r2=0.1, a physical 
distance threshold of 500Kb, preferentially retaining the 
SNP most significantly associated with AD (2). The AD 
GWAS association p-value threshold for SNP inclusion 
was 0.5, as this currently maximally captures polygenic 
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risk in the greatest number of samples (1). The models 
were fitted using IGAP (stage I) summary statistics data 
as a training set and predicting AD/control status in our 
study. We note that our cohort is part of the IGAP study 
(5) and therefore the results maybe slightly biased due 
to the 1.3% overlap. To adjust for the overlap, we used 
a simulation approach as described in (2), assuming that 
our dataset (N=686) is a random subset of the IGAP study 
(N=54,162).  In short, we simulated 1000 times effect sizes 
of SNPs with mean b~N(BIGAP, sd=0.12*SEIGAP), where 
BIGAP is the beta-coefficient and SEIGAP is the standard 
error for that SNP in the IGAP study, and the coefficient 
0.12 was estimated empirically (see (2) for details).
Results
The predict ion accuracy (AUC) in the ful l 
pathologically confirmed dataset was AUC=0.73 [0.71-
0.75] for E4 alleles and AUC= 0.75 [0.73-0.77] for E4 and 
E2.  When PRS was included to the predictive model, 
the AUC for the full pathologically confirmed dataset 
was 0.84, after adjusting for the overlap with the training 
IGAP dataset used for SNP selection (2). The original 
unadjusted AUC was 0.87 and was 0.84, after adjusting 
for the overlap with the training set used for SNP 
selection (2).
Removing all individuals with an E4 allele only 
reduced the unadjusted AUC from 0.87 to 0.84 and then 
removing all E2 carriers (i.e. restricting the analysis to 
E3 homozygotes) had a further small effect and reduced 
the AUC to 0.83.  Thus, in contrast to the results obtained 
with the clinical series, the AUC is only marginally 
reduced by removing E4 and E2 carriers. 
We tested three possible explanations for this finding: 
1) the people who get AD without an E4 allele have more 
AD risk alleles, i.e. alleles at other loci have bigger effects 
in the absence of E4; 2) the effects of APOE and other 
risk SNPs are independent; 3) the results are driven by 
inflation due to the overlap between the discovery (IGAP) 
and test (E3 homozygote pathologically confirmed AD 
cases and controls) datasets.
First, we ran a GWAS analysis with snptest software 
only for E3 homozygote cases and controls. The 
majority of the top IGAP SNPs did not show statistically 
significant association in this small sample set and their 
effect sizes were not higher than the effect sizes in the 
whole data set (data not shown).  This strongly suggests 
that the E3 homozygotes with disease do not have a 
greater excess of other AD risk alleles. 
Next, we counted the number of risk and alternative 
alleles for sets of SNPs at different significance thresholds 
(reported by the IGAP study) for each subject in the E3 
homozygote subgroup and in the rest of the dataset. We 
compared the average number of risk and alternative 
alleles (per person) using a chi-square test for a 2x2 table: 
(Risk Allele - Alternative Allele) x (E3 homozygotes 
– other genotypes). This analysis was performed in 
cases and controls separately as cases in general may 
have more risk alleles than controls. The results are 
summarized in Tables 1 and 2, respectively. There were 
no significant differences in the mean number of risk and 
alternative alleles per person among the E3 homozygotes 
versus the other genotypes in either the pathologically 
confirmed AD cases or the pathologically confirmed 
controls.
We also compared the predictive accuracy of the 
best model (PRS for SNPs with p-values≤0.5) with and 
without APOE in three subgroups, namely E4 carriers 
(644 cases and 115 controls), E4 and E2 carriers (677 cases 
and 204 controls) and E3 homozygotes (321 cases and 
365 controls). Table 3 shows the estimated AUC in those 
subgroups for the PRS models with more significant 
SNPs (p≤0.001 in IGAP study) and the best predictive 
PRS model (1), combining all available independent SNPs 
with p-values ≤0.5, when the APOE region is included 
and excluded. The results clearly show that the PRS 
predictive accuracy is almost the same in any subgroup, 
when APOE is excluded. Note that the full dataset 
Table 1. Comparison of the mean numbers of risk and alternative alleles per person in E3 homozygotes vs other AD 
cases. APOE region is excluded
SNP selection threshold E3  homozygotes Other genotypes OR P
Mean No of risk 
alleles
Mean No of alternative 
alleles
Mean No of risk 
alleles
Mean No of alternative 
alleles
0.0001 92.5 63.3 91.0 63.6 1.016 1
0.001 306.6 282.2 299.9 283.8 1.022 0.859
0.01 1777.9 1576.4 1766.1 1580.1 1.007 0.874
0.05 7348.8 6333.3 7315.1 6346.3 1.005 0.794
0.1 13329.7 11633.7 13300.3 11661.5 1.002 0.805
0.2 23935.0 21032.8 23868.4 21084.1 1.003 0.701
0.3 33149.4 29575.3 33081.5 29657.7 1.002 0.673
0.4 41612.3 37349.4 41561.4 37436.3 1.001 0.729
0.5 49267.5 44544.9 49197.0 44643.4 1.001 0.697
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(shown in the second column of Table 3), has the largest 
overlap with IGAP, and therefore the AUC estimate 
for this group has the most (~2%) inflation (see (2) for 
details). 
Finally, we adjusted our main result (AUC=0.83 in 
the E3 homozygote dataset) for the overlap with the 
discovery IGAP dataset using a simulation approach (2). 
The adjusted AUC and the confidence intervals were 
calculated as average AUC and CI over 1000 simulations, 
AUCADJ = 0.83 [95% CI: 0.80-0.86].  
Figure 2 shows the distribution of standardized 
PRS for the E3 homozygote cases and E3 homozygote 
controls. In the negative polygenic extreme group (PRS 
smaller than -2), there were 17 controls and 0 cases. In the 
positive extreme group (PRS greater than 2), there were 
11 cases and 1 control. Looking at the extremes (PRS < 
-1.5) and (PRS > 1.5), there were 1 case and 49 controls 
and 41 cases and 4 controls, respectively.
Table 2. Comparison of the mean numbers of risk and alternative alleles per person in E3 homozygotes vs other 
controls. APOE region is excluded
SNP selection threshold E3 homozygotes Other genotypes OR P
Mean No of risk 
alleles
Mean No of alternative 
alleles
Mean No of risk 
alleles
Mean No of alternative 
alleles
0.0001 87.6 66.8 88.4 67.7 0.991 1.00
0.001 293.8 293.2 292.8 295.4 1.003 0.973
0.01 1727.4 1621.3 1723.0 1623.0 1.003 0.961
0.05 7181.6 6461.3 7153.8 6471.3 1.004 0.833
0.1 13070.4 11836.9 13037.7 11860.3 1.003 0.810
0.2 23540.4 21344.5 23466.5 21388.0 1.003 0.703
0.3 32649.2 29969.2 32573.0 30039.3 1.002 0.684
0.4 41028.5 37805.2 40983.2 37869.4 1.001 0.785
0.5 48618.4 45048.2 48564.7 45118.6 1.001 0.776
Table 3. AUC for PRS models with IGAP-based p-value SNP selection thresholds 0.001 and 0.5. These results are not 
unadjusted for IGAP/Corneveaux overlap
PRS model AUC and 95% Confidence intervals in “[]”
whole sample E4 carriers E4E2 carriers E3 homozygotes
PRS with SNPs p≤0.001 0.741 [0.72-0.78] 0.616 [0.56-0.67] 0.743 [0.70-0.78] 0.632 [0.59-0.67]
PRS with SNPs p≤0.5 0.866* [0.85-0.89] 0.831 [0.78-0.88] 0.868 [0.84-0.90] 0.831 [0.80-0.86]
PRS with SNPs p≤0.001
APOE region excluded
0.637 [0.61-0.67] 0.565 [0.51-0.62] 0.625 [0.58-0.67] 0.646 [0.61-0.69]
PRS with SNPs p≤0.5 
APOE region excluded
0.840 [0.82-0.86] 0.821 [0.77-0.87] 0.837 [0.80-0.87] 0.834 [0.80-0.86]
* This AUC is reported in (2).
Figure 1. Polygenic Risk Score with E4 allele carriers 
omitted and in E3 homozygotes
Figure 2. Distribution of standardised and PCA adjusted 
PRS in E3E3 cases and controls
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Discussion
Our results show that the predictive accuracy of 
PRS in pathologically confirmed E3 homozygotes is 
high and equivalent to the predictive accuracy of the 
whole dataset.  This finding indicates that APOE is an 
independent risk factor for the disease. This result is in 
contrast to the PRS observed in clinical cohorts where 
restricting analyses to E3 homozygotes resulted in a 
large reduction in the PRS accuracy.  We believe this is 
likely to be because of poor diagnostic accuracy among 
those labeled as AD in the absence of an E4 allele: this 
interpretation is consistent with post mortem follow 
up of AD clinical trials, which suggested a diagnostic 
inaccuracy of up to 25% (6, 7).  From a mechanistic 
perspective, this result suggests that the genetic 
architecture of AD in E3 homozygotes is similar to that 
in the other APOE genotypes since a similar proportion 
of risk is captured by PRS in all genotypes.  This result 
does not support the belief that E3 homozygotes with 
AD have more predisposing variants at other loci.  This 
result suggests that PRS analysis is likely to have utility in 
clinical trial design.
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